|
|
News Breaks | | | | February 27, 2013 | | 09:19 EDT |  | BRLI | Bio-Reference Labs will offer non-invasive prenatal testing from Natera
Bio-Reference Labs announced that the company and Natera have entered into a definitive agreement to commercialize the Panorama non-invasive prenatal screening test developed by Natera. The Panorama test will be sold by the GenPath business unit of Bioreference. Panorama is a simple blood test that uses cutting-edge genotyping and sequencing technologies to identify chromosomal aneuploidies such as trisomies 13, 18, 21, and certain sex-chromosome abnormalities. According to the proceedings of the recent Society of Maternal Fetal Medicine conference held in San Francisco, non-invasive prenatal tests can reduce fetal loss by up to 91% while detecting the same amount of aneuploidies 13, 18, 21 by avoiding invasive Amniocentesis and chorionic villi sampling procedures. Panorama can be used starting 9th week of pregnancy. | |
|
News For BRLI From The Last 14 Days Check below for free stories on BRLI the last two weeks. |
|
|
| May 22, 2013 | | 11:23 EDT |  | BRLI | Rumor: Bio-Reference Labs moves up on renewed takeover chatter
 Subscribe for More Information | | | May 16, 2013 | | 09:54 EDT |  | BRLI | Bio-Reference Labs references new relationship at conference, says BofA/Merrill
Subscribe for More Information | |
|
|
|
|
|
|
